Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Oncgnostics GmbH cooperates with SAYRE Therapeutics in IndiaBy: oncgnostics GmbH GynTect is a molecular test, which allows timely clarification, if a patient with abnormal Pap test finding and/or a positive test for the cancer-causing human papillomaviruses already has or develops a cervical disease that requires treatment. The test provides fast and reliable results and thus quick certainty for the patient. This facilitates the risk assessment for the patient drastically: Dr. Alfred Hansel, CEO at oncgnostics, stated "India has the highest prevalence of cervical cancer world-wide with high mortality rates and with the country's dedicated efforts toward cervical cancer screening , the Indian subcontinent is an attractive market for oncgnostics." Vandana Subramanian, Head- Business Development at Sayre stated, " Cervical cancer, caused by Human Papillomavirus infection, is the leading cancer in Indian women, accounting to nearly 1/4th of the global cervical cancer incidences as well as deaths. Our collaboration with oncgnostics provides a tremendous boost in our efforts to bring cutting-edge molecular diagnostic products to the Indian subcontinent. Sayre is committed to making available life-saving medicines, devices and diagnostics in South Asia, to benefit the patient community and improve their quality of life." ---------------------------------- Links: Further information about GynTect® as well as the test procedure, are found here: http://www.oncgnostics.com/ Find cost-free picture material concerning this press release, the test and the company here: http://oncgnostics.com/ End
|
|